News of Royal DSM’s offer to acquire Martek Biosciences Corp. for $1.09 billion was seen as a positive step for both companies today, with Martek shares surging on the news and market analysts praising DSM for striking a “sound strategic” deal with the algae-based omega-3 company. DSM is paying $31.50 per share, which is a 35 percent premium over Martek’s closing share price on Monday. Analysts report that the 8.5-times EBITDA price DSM is paying for Martek is in line with recent industry acquisitions, including BASF.

As analysts have also noted, the move is in line with DSM’s strategy of shifting its focus from traditional chemicals to nutrition and pharmaceutical products. “The nutrition area is a key area of growth for us,” DSM board member Stephen Tanda told NewHope360.

The deal is significant news for the global nutritional ingredients market because it represents DSM’s largest nutrition investment since the company purchased Roche’s vitamins and fine chemicals division in 2002. Perhaps more important, it adds to the competition and complexity of the global omega-3 market.